Showing 3771-3780 of 4164 results for "".
- Staar Surgical Celebrates Milestone and Unveils New EVO ICL Data at ASCRShttps://modernod.com/news/staar-surgical-celebrates-milestone-and-unveils-new-evo-icl-data-at-ascrs/2482194/At the ASCRS annual meeting in Boston, April 5-8, 2024, Staar Surgical will be celebrating a commercial milestone: 3 million lenses sold. Staar will be showcasing the clinical, practice and innovation advantages of the EVO ICL through a series of posters, presentations and educational p
- Aldeyra Plans to Resubmit New Drug Application for Reproxalap in Dry Eye Diseasehttps://modernod.com/news/aldeyra-plans-to-resubmit-new-drug-application-for-reproxalap-in-dry-eye-disease/2482193/About 4 months after receiving a complete response letter (CRL) from the FDA, Aldeyra Therapeutics announced a clinical development plan intended to enable resubmission of a new drug application (NDA) of topical ocular 0.25% reproxalap, an investigational RASP modulator, for the treatment of dry
- ViaLase Closes $40 million Series C Financing to Advance First Femtosecond Laser for the Treatment of Glaucomahttps://modernod.com/news/vialase-closes-40-million-series-c-financing-to-advance-first-femtosecond-laser-for-the-treatment-of-glaucoma/2482192/ViaLase has closed a Series C financing with proceeds of approximately $40 million to continue advancement of clinical, regulatory, and commercial milestones of the company's ViaLase Laser. If approved, the ViaLase Laser will be the first femtosecond laser used for the tre
- Opus Genetics Completes Dosing in First Cohort of Phase 1/2 Trial of Gene Therapy OPGx-LCA5https://modernod.com/news/opus-genetics-completes-dosing-in-first-cohort-of-phase-12-trial-of-gene-therapy-opgx-lca5-in-patients-with-lca5/2482180/Opus Genetics announced that the first cohort has completed dosing in its open-label, dose-escalation phase 1/2 clinical trial evaluating the subretinal delivery of OPGx-LCA5, an adeno-associated virus 8 (AAV8) vector designed to precisely deliver a functional LCA5 gene to the oute
- BlueRock Therapeutics and Foundation Fighting Blindness Partner for IRD Studyhttps://modernod.com/news/bluerock-therapeutics-and-foundation-fighting-blindness-partner-for-ird-study/2482178/BlueRock Therapeutics LP, a clinical stage cell therapy company and subsidiary of Bayer, and Foundation Fighting Blindness announced a collaboration to add a new cohort to the Foundation’s 'Uni-Rare natural history study' of people living with inherited retinal diseases (I
- GenSight Biologics Confirms Sustained Efficacy and Safety of Lumevoq Injections 4 Years After One-Time Administrationhttps://modernod.com/news/gensight-biologics-confirms-sustained-efficacy-and-safety-of-lumevoq-injections-4-years-after-one-time-administration/2482174/GenSight Biologics reported initial efficacy and safety results at 4 years post-treatment administration in the REFLECT phase 3 clinical trial with Lumevoq (GS010; lenadogene nolparvovec). The results show that 4 years after a one-ti
- Atsena Therapeutics Initiates Dosing in Second Cohort of Phase 1/2 Trial Evaluating XLRS Gene Therapyhttps://modernod.com/news/atsena-therapeutics-initiates-dosing-in-second-cohort-of-phase-12-trial-evaluating-xlrs-gene-therapy/2482162/Dosing has been initiated in the second cohort of the LIGHTHOUSE study, a phase 1/2 clinical trial evaluating subretinal injection of ATSN-201 for the treatment of X-linked retinoschisis (XLRS), according to Atsena Therapeutics. ATSN-201, a gene therapy product candidate,
- SDC Transitions its Ophthalmic Biometric Division to Ora Inc.https://modernod.com/news/sdc-transitions-its-ophthalmic-biometric-division-to-ora-inc/2482149/Statistics & Data Corporation (SDC) has decided to transition its ophthalmic biometric division to its partner Ora Inc. Since 2005, SDC’s partnership and common ownership with Ora has provided clinical trial services in ophthalmology, while allowing S
- Palitin Misses Co-Primary Endpoints in Phase 3 Dry Eye Disease Trialhttps://modernod.com/news/palitin-misses-co-primary-endpoints-in-phase-3-trial-dry-eye-disease-candidate/2482136/Palatin Technologies did not achieve statistical significance in the co-primary endpoints of its pivotal phase 3 clinical trial evaluating the safety and efficacy of PL9643 versus vehicle in the treatment of dry eye disease (DED). MELODY-1 had two co-primary efficacy endpoints
- Opthea Completes Enrollment in First Pivotal Trial of Sozinibercept for Wet AMDhttps://modernod.com/news/opthea-completes-enrollment-in-first-pivotal-trial-with-sozinibercept/2482114/Opthea announced it has completed enrollment of all patients in the COAST phase 3 pivotal clinical trial investigating sozinibercept (OPT-302, a vascular endothelial growth factor (VEGF)-C/D inhibitor) in combination with aflibercept, an anti-VEGF-A therapy, for the treatment of wet age-rela